{
    "clinical_study": {
        "@rank": "117798", 
        "arm_group": {
            "arm_group_label": "maintenance therapy", 
            "arm_group_type": "Experimental", 
            "description": "Initially, all subjects received 8 cycles of Cetuximab (400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks)plus FOLFIRI (irinotecan 180 mg/m2 IV on day 1 , leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and  fluorouracil 2400mg/m2 civ46h every 2 weeks) .\nAfter 8 cycles or severe toxicity, patients received maintenance therapy comprising Cetuximab (250mg/m2 every week or 500mg/m2 every 2 weeks) and either irinotecan( 180 mg/m2 IV every 2 weeks) or  fluorouracil  arm( leucovorin  400mg/m2 on day 1 , fluorouracil  400mg/m2 on day 1 and  fluorouracil  2400mg/m2 civ46h every 2 weeks ). In cases of unacceptable toxicity, only the related medication was stopped"
        }, 
        "brief_summary": {
            "textblock": "1. To evaluate efficacy, safety, and feasibility of maintenance therapy with Cetuximab\n           combined with irinotecan or fluorouracil after Cetuximab plus  irinotecan and\n           fluorouracil(FOLFIRI)  in patients with incurable colorectal cancer.\n\n        2. The relevant phase III studies reported that the  progression free-survival of\n           cetuximab combined with FOLFIRI in advanced colorectal cancer was 4.3 months up to 6.8\n           months.\n\n      This study assumed that the progression free-survival was 5.1 months  which was not inferior\n      to the continuous chemotherapy"
        }, 
        "brief_title": "Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Incurable Colorectal Cancer", 
            "RAS-wild-type"
        ], 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients aged \u226518 years with histologically confirmed metastatic colorectal cancer\n\n          2. Eastern Cooperative Oncology Group performance status \u22642 and\n\n          3. life expectancy of >3 months were enrolled.\n\n          4. All patients had to have at least one measurable lesion according to the Response\n             Evaluation Criteria in Solid Tumors (RECIST, version 1.1)\n\n          5. None was previous exposure to Cetuximab or irinotecan .\n\n          6. Patients had to have adequate haematological (absolute neutrophil count >1.5 \u00d7 109/l;\n             platelet count >100 \u00d7 109/l; haemoglobin >9 g/dl), hepatic [total bilirubin <1.5 \u00d7\n             the upper limit of normal (ULN); alanine aminotransferase and aspartate\n             aminotransferase <2.5 \u00d7 ULN, or <5 \u00d7 ULN in the case of hepatic metastases or <10 \u00d7\n             ULN in the case of osseous metastases; alkaline phosphatase <2.5 \u00d7 ULN, or <5 \u00d7 ULN\n             or <10 \u00d7 ULN in the case of hepatic or osseous metastases, respectively] and renal\n             function (creatinine clearance \u226560 ml/min)\n\n          7. All RAS were wildtype. -\n\n        Exclusion Criteria:\n\n          1. Pregnant or breast-feeding women;\n\n          2. Clinically significant cardiac disease;\n\n          3. Lack of physical integrity of the upper gastrointestinal tract;\n\n          4. History of other malignancy;\n\n          5. Central nervous system metastases. -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071069", 
            "org_study_id": "ZS-ON-05"
        }, 
        "intervention": [
            {
                "arm_group_label": "maintenance therapy", 
                "description": "400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "maintenance therapy", 
                "description": "180 mg/m2 IV every 2 weeks", 
                "intervention_name": "irinotecan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "maintenance therapy", 
                "description": "400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks", 
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug", 
                "other_name": "5FU"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Irinotecan", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Incurable colorectal cancer", 
            "maintenance therapy", 
            "Cetuximab"
        ], 
        "lastchanged_date": "February 23, 2014", 
        "location": {
            "contact": {
                "email": "liu.tianshu@zs-hospital.sh.cn", 
                "last_name": "Tianshu Liu, Doctor"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Zhongshan Hospital Affiliated to Fudan University"
            }, 
            "investigator": {
                "last_name": "Yiyi yu, Master", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficacy and Tolerance of Cetuximab Combined With Irinotecan or Fluorouracil as Maintenance Therapy in Patients With RAS-wild-type Incurable Advanced Colorectal Cancer \uff08Confirm Study\uff09", 
        "overall_contact": {
            "email": "liu.tianshu@zs-hospital.sh.cn", 
            "last_name": "Tianshu Liu, Doctor", 
            "phone": "+861368 1973 996"
        }, 
        "overall_contact_backup": {
            "email": "yu.yiyi@zs-hospital.sh.cn", 
            "last_name": "yiyi yu, Master", 
            "phone": "+86 1381 6730 912"
        }, 
        "overall_official": {
            "affiliation": "Medicine-Oncology Derpartment of Zhongshan hospital", 
            "last_name": "Tianshu Liu, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "defined as the time from enrollment  to progression or death RECIST guidelines were used to define all responses after patients had received every 8 weeks of therapy", 
            "measure": "The progression free-survival", 
            "safety_issue": "No", 
            "time_frame": "8 Months after the last subject participate in"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071069"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Zhongshan Hospital", 
            "investigator_full_name": "Tianshu Liu", 
            "investigator_title": "Director of Medicine-Oncology department", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "defined as the time from enrollment to death", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "18 Months after the last subject participate in"
            }, 
            {
                "description": "Toxicity was graded according to the criteria of the National Cancer Institute Common Terminology for Adverse Events (version 4.0).", 
                "measure": "Grade 3 and 4 adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "3 Months after the last subject end the treatment"
            }
        ], 
        "source": "Shanghai Zhongshan Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tianshu Liu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}